← All drugs built on NIH-funded research

Eli Lilly · Florbetapir F-18

Amyvid: patented from NIH-funded research

University of Pennsylvania reported 2 patents on this drug to NIH as inventions made with NIH grant money. Avid Radiopharmaceuticals lists them with the FDA as protecting Amyvid.
Patent reported to NIH as grant-funded

Medicare paid, 2024

—

before rebates

Medicare, 2020–2024

$0

Medicaid paid, 2024

$124K

before rebates

NIH grants behind the patents

$3.4M

whole-grant totals, not the drug's cost

The public record, link by link

  1. 1 · Public money

    2 NIH grants to University of Pennsylvania, $3.4M in all.

  2. 2 · Patent

    7687052, 8506929, reported to NIH under R01AG022559, R21AG021868.

  3. 3 · FDA approval

    Approved Apr 6, 2012, held by Avid Radiopharmaceuticals (NDA 202008).

  4. 4 · Public pays

    Medicaid paid $124K in 2024. It is not in Medicare's drug spending files.

The grants

Totals are everything NIH paid on each grant since 1985. A grant usually funded more than this one invention.
GrantResearchYearsNIH paid
R01AG022559

NIA

PET Imaging of Abeta Plaques in Alzheimer?s Disease

University of Pennsylvania

2004–2011$2.2M
R21AG021868

NIA

SPECT Imaging of Abeta Plaques in Brain

University of Pennsylvania

2002–2006$1.2M

The patents

Patents the FDA lists for this drug that were also reported to NIH as grant-funded inventions.
  • US 7687052

    Stryrylpyridine derivates and theur use for binding and imaging amylod plaques

    Reported by University of Pennsylvania

    FDA-listed expiry Apr 30, 2027
  • US 8506929

    Styrylpyridine Derivatives and Their Use for Binding and Imaging Amyloid Plaques

    Reported by University of Pennsylvania

    FDA-listed expiry Apr 30, 2027

Eli Lilly's side

Drug makers pay for the clinical trials that take a compound from the lab to FDA approval, and they often license the patent from the university and pay royalties on sales. Those terms are not public. The FDA's approval records for Amyvid are linked above, and Eli Lilly's page shows its other drugs on this list. If Eli Lilly wants to add its account, we will publish it here.

How this is built. Universities and companies that use NIH grants must report the inventions those grants produce to NIH, under the Bayh-Dole Act. NIH publishes the patent numbers and the grants they were reported under. We match those patents to the patents drug makers list with the FDA for each approved drug (the Orange Book), then add what Medicare Part D, Part B and Medicaid paid for each drug. Only patents still listed with the FDA appear, so drugs whose patents have expired drop out, and biologics, which the Orange Book does not cover, are not here yet.

What the numbers mean. "NIH grants" is everything NIH paid out on the grants a patent was reported under, from 1985 on. A grant usually paid for more than the one invention, so it is not the cost of the drug. Medicare and Medicaid figures are gross spending before the rebates drug makers pay back, which are confidential. Companies also paid for the clinical trials that took these drugs to approval; each drug page links the company's own filings.

Sources: NIH RePORTER patents reported under NIH grants (from iEdison); NIH RePORTER project funding; FDA Orange Book patent and product files; Medicare Part D Spending by Drug; Medicare Part B Spending by Drug; Medicaid Spending by Drug. Updated 2026-11-05.